Pharmaceutical Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X
Analysis

Using shark antibodies to treat Alzheimer’s disease

Dutch biotech company Crossbeta Biosciences has been granted an exclusive license to three beta-amyloid oligomer (AßO)-specific shark antibodies, identified under a collaboration with Australian company AdAlta. These ‘i-bodies’ are considered to have huge disease-specific potential for the diagnosis and treatment of Alzheimer’s disease, but how do they work? Abi Millar finds out.

Go Top